2005 Annual Meeting | Neurological Complications of Systemic Cancer

Date Monday 04/11/05

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) John W. Henson, MD, FAAN

Topic(s) Neuro-oncology

Learning Objectives Upon completion:
Participants should be familiar with the neurological presentations of systemic cancer and be able to diagnose and treat or recommend appropriate treatment for metastatic complications of cancer and cancer therapy.

The American Board of Psychiatry and Neurology has reviewed Neurological Complications of Systemic Cancer and has approved this product as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
09:00 AM - 09:45 AM		Diagnosis and Treatment of Brain Metastasis Roy A. Patchell, MD
09:45 AM - 10:30 AM		Diagnosis and Treatment of Leptomeningeal Metastasis Marc Chamberlain, MD
10:30 AM - 10:45 AM		Break
10:45 AM - 11:30 AM		Neurological Complications of Radiation and Chemotherapy Kurt A. Jaeckle, MD, FAAN
11:30 AM - 12:15 PM		Paraneoplastic Neurological Syndromes Josep O. Dalmau, MD, PhD, FAAN
12:15 PM - 12:45 PM		Case Studies

Faculty Disclosures
Josep O. Dalmau, MD, PhD, FAAN	Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas Research Institute of America. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Research & Development . Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ��ɫ��. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Euroimmun, Inc. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care.
Roy A. Patchell, MD	No disclosure on file
Marc Chamberlain, MD	No disclosure on file
Kurt A. Jaeckle, MD, FAAN	Dr. Jaeckle has stock in Entegrion, Inc.
John W. Henson, MD, FAAN	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��